CTOs on the Move

Basic Research

www.basicresearch.org

 
Basic Research, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

ARYx Therapeutics

ARYx Therapeutics, Inc. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellular Engineering Technologies

Cellular Engineering Technologies is a Iowa City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Skinvisible Pharmaceuticals

Skinvisible Pharmaceuticals is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Care Solace

Care Solace is a social purpose organization founded with the mission to implement systemic solutions for sustainable, equitable access to mental health care. Providing a human and technology approach, Care Solace navigates the mental health care system and finds the right help for everyone in every community regardless of coverage, including private insurance, Medicaid, and sliding scale options for those without insurance. We match individuals to more than 350,0000 verified providers, perform a Warm Handoff®, and follow-up on care. Care Solace expands on existing social programs and employer EAPs and bridges the gaps for needs that exceed the scope of those services. Founded in 2017, Care Solace has proudly completed over 6.5 million support interactions across 600 organizations nationwide.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.